Cargando…

Acquired resistance to irradiation or docetaxel is not associated with cross-resistance to cisplatin in prostate cancer cell lines

PURPOSE: Platinum chemotherapy can be considered to treat metastatic castration-resistant prostate cancer (mCRPC) with features of neuroendocrine differentiation. However, platinum compounds are generally only applied after the failure of multiple prior-line treatment options. This study investigate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Donix, Lukas, Erb, Holger H. H., Peitzsch, Claudia, Dubrovska, Anna, Pfeifer, Manuel, Thomas, Christian, Fuessel, Susanne, Erdmann, Kati
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article – Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114061/ https://www.ncbi.nlm.nih.gov/pubmed/35020044 http://dx.doi.org/10.1007/s00432-022-03914-5

Ejemplares similares

Comprehensive Evaluation of Multiple Approaches Targeting ABCB1 to Resensitize Docetaxel-Resistant Prostate Cancer Cell Lines
por: Linke, Dinah, et al.
Publicado: (2022)

Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer
por: Erb, Holger H. H., et al.
Publicado: (2020)

Carbon nanomaterials sensitize prostate cancer cells to docetaxel and mitomycin C via induction of apoptosis and inhibition of proliferation
por: Erdmann, Kati, et al.
Publicado: (2017)

Overexpression of claspin promotes docetaxel resistance and is associated with prostate‐specific antigen recurrence in prostate cancer
por: Babasaki, Takashi, et al.
Publicado: (2021)

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
por: Mohr, Lisa, et al.
Publicado: (2017)

Artesunate Inhibits the Growth Behavior of Docetaxel-Resistant Prostate Cancer Cells
por: Vakhrusheva, Olesya, et al.
Publicado: (2022)

Targeting mTOR Complex 2 in Castration-Resistant Prostate Cancer with Acquired Docetaxel Resistance
por: Huang, Yujie, et al.
Publicado: (2022)

Neutropenia and docetaxel exposure in metastatic castration‐resistant prostate cancer patients: A meta‐analysis and evaluation of a clinical cohort
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2019)

Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer
por: Passildas‐Jahanmohan, Judith, et al.
Publicado: (2021)

Linking NRP2 With EMT and Chemoradioresistance in Bladder Cancer
por: Schulz, Alexander, et al.
Publicado: (2020)

Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice
por: de Groot, Ietsen, et al.
Publicado: (2021)

Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice
por: Lendorf, Maria Elisabeth, et al.
Publicado: (2021)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

Computer-aided analysis of quercetin mechanism of overcoming docetaxel resistance in docetaxel-resistant prostate cancer
por: Omoboyede, Victor, et al.
Publicado: (2023)

Resensitization of cisplatin resistance ovarian cancer cells to cisplatin through pretreatment with low‐dose fraction radiation
por: Zhao, Lili, et al.
Publicado: (2019)

Docetaxel, Cisplatin, and 5‐Fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma
por: Fiteni, Frédéric, et al.
Publicado: (2016)

Molecular mechanisms of docetaxel resistance in prostate cancer
por: Sekino, Yohei, et al.
Publicado: (2020)

Overcoming cisplatin resistance in osteosarcoma through the miR-199a-modulated inhibition of HIF-1α
por: Keremu, Ajimu, et al.
Publicado: (2019)

Systemic Triple Therapy in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Ready for Prime Time or Still to Be Explored?
por: Thomas, Christian, et al.
Publicado: (2021)

The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance
por: Bascetta, Lorenzo, et al.
Publicado: (2017)

γ-Klotho is correlated with resistance to docetaxel in castration-resistant prostate cancer
por: Onishi, Kenta, et al.
Publicado: (2020)

Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma
por: Hastings, Jordan F, et al.
Publicado: (2020)

Elevated expression of prostate cancer-associated genes is linked to down-regulation of microRNAs
por: Erdmann, Kati, et al.
Publicado: (2014)

Randomized phase II trial of S‐1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non‐small cell lung cancer
por: Shimokawa, Tsuneo, et al.
Publicado: (2020)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells
por: Wang, Quan, et al.
Publicado: (2018)

Curcumin Nanoparticles and Their Cytotoxicity in Docetaxel-Resistant Castration-Resistant Prostate Cancer Cells
por: Tanaudommongkon, Irin, et al.
Publicado: (2020)

FBP1 knockdown decreases ovarian cancer formation and cisplatin resistance through EZH2-mediated H3K27me3
por: Xiong, Xifeng, et al.
Publicado: (2022)

Clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer
por: Lin, Guo-Wen, et al.
Publicado: (2019)

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
por: Diaz Osterman, Carlos J, et al.
Publicado: (2019)

Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer
por: Wilson, C, et al.
Publicado: (2008)

Tau oligomers accumulation sensitizes prostate cancer cells to docetaxel treatment
por: Martellucci, Stefano, et al.
Publicado: (2021)

Evaluation of MicroRNAs as Non-Invasive Diagnostic Markers in Urinary Cells from Patients with Suspected Prostate Cancer
por: Borkowetz, Angelika, et al.
Publicado: (2020)

Characterisation and manipulation of docetaxel resistant prostate cancer cell lines
por: O'Neill, Amanda J, et al.
Publicado: (2011)

Overcoming docetaxel resistance in prostate cancer: a perspective review
por: Hwang, Clara
Publicado: (2012)

Role of microRNAs in the resistance of prostate cancer to docetaxel and paclitaxel
por: Kopczyńska, Ewa
Publicado: (2016)

Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer
por: Mittal, Karuna, et al.
Publicado: (2017)

TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer
por: Sekino, Yohei, et al.
Publicado: (2019)

Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non‐small cell lung cancer: Analysis of dose‐volume parameters
por: Katsui, Kuniaki, et al.
Publicado: (2020)

Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer
por: Wu, Meng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_afuejsbjkrkcjh9ppe8gi6qqpe